- Home
- IMMX vs MIST Comparison
IMMX vs MIST Comparison
Compare IMMX & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- MIST
- Stock Information
- Founded
- IMMX 2014
- MIST 2003
- Country
- IMMX United States
- MIST Canada
- Employees
- IMMX N/A
- MIST N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- MIST Health Care
- Exchange
- IMMX Nasdaq
- MIST Nasdaq
- Market Cap
- IMMX 50.1M
- MIST 53.9M
- IPO Year
- IMMX 2021
- MIST N/A
- Fundamental
- Price
- IMMX $2.09
- MIST $1.11
- Analyst Decision
- IMMX Strong Buy
- MIST Strong Buy
- Analyst Count
- IMMX 1
- MIST 2
- Target Price
- IMMX $7.00
- MIST $9.50
- AVG Volume (30 Days)
- IMMX 59.6K
- MIST 1.6M
- Earning Date
- IMMX 05-20-2025
- MIST 05-20-2025
- Dividend Yield
- IMMX N/A
- MIST N/A
- EPS Growth
- IMMX N/A
- MIST N/A
- EPS
- IMMX N/A
- MIST N/A
- Revenue
- IMMX N/A
- MIST N/A
- Revenue This Year
- IMMX N/A
- MIST N/A
- Revenue Next Year
- IMMX N/A
- MIST N/A
- P/E Ratio
- IMMX N/A
- MIST N/A
- Revenue Growth
- IMMX N/A
- MIST N/A
- 52 Week Low
- IMMX $1.26
- MIST $0.63
- 52 Week High
- IMMX $2.71
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- IMMX 61.41
- MIST 43.96
- Support Level
- IMMX $1.92
- MIST $1.28
- Resistance Level
- IMMX $2.25
- MIST $1.32
- Average True Range (ATR)
- IMMX 0.17
- MIST 0.12
- MACD
- IMMX 0.03
- MIST 0.02
- Stochastic Oscillator
- IMMX 67.61
- MIST 27.39
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).